We found that acquiring sensitivity to venetoclax is based on gaining BCL-2 dependence, partly based on STAT3-dependent increased BCL-2 expression in chronic ibrutinib-resistant CLL and DLBCL cells (Kapoor, I et al., unpublished). Here, BCL2 is linked to diffuse large B-cell lymphoma.